P1, N=27, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Sep 2026 | Trial primary completion date: Nov 2025 --> Sep 2026
12 months ago
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, causing >10,000 deaths per year in the United States. Moreover, DAC treatment resulted in downregulation of DNA repair pathways, β-Catenin, and Notch signaling pathways.Taken together, we found that the antileukemia activity of CD33 CAR T cells was enhanced by pretreatment of leukemia cells with DAC. This combination represents a clinically relevant therapy for the treatment of patients with r/r AML.